Cambridge Immunology Network
Type 1 diabetes (T1D) is an autoimmune disease that results from a complex interplay of genetics and environmental factors, leading to a dysregulated immune system and loss of peripheral and central tolerance. The DIL studies the aetiology of T1D, aiming to identify disease-associated molecules and pathways that could be targeted for therapeutic intervention. We are currently investigating immunotherapy with interleukin-2 to rebalance the immune system and restore Treg-mediated tolerance. I am investigating the immunotherapeutic potential of IL-2, attempting to specifically increase the number and function of Tregs both in humans and preclinical animal models, and investigating biomarkers of activity of IL-2 treatment.
Cambridge Immunology Network Coordinator
University of Cambridge Department of Medicine,
Jeffrey Cheah Biomedical Centre,
Cambridge Biomedical Campus, Puddicombe Way,
Cambridge, CB2 0AW
Follow us on Twitter
Watch our webinars
Sign up to our newsletter
FCEs provide interdisciplinary training programmes for students, fellows and continuing education physicians through FOCIS assisted opportunities
© 2025 University of Cambridge